Sign in

    Mazahir Alimohamed • Leerink Partners

    Mazahir Alimohamed's questions to Aquestive Therapeutics Inc (AQST) leadership

    Mazahir Alimohamed's questions to Aquestive Therapeutics Inc (AQST) leadership • Q2 2025

    Question

    Mazahir Alimohamed of Leerink Partners inquired about the likelihood of an FDA Advisory Committee (AdCom) meeting for Anafilm and the company's confidence in its clinical data package.

    Answer

    CEO Daniel Barber stated that Aquestive expects clarity on a potential AdCom in the coming weeks following the FDA's mid-cycle review and that the company is prepared. Chief Medical Officer Dr. Carl Kraus affirmed confidence in the robust clinical package, highlighting it as one of the largest epinephrine studies conducted, with 10 independent studies and over 930 exposures.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Lantheus Holdings Inc (LNTH) leadership

    Mazahir Alimohamed's questions to Lantheus Holdings Inc (LNTH) leadership • Q2 2025

    Question

    Mazahir Alimohamed of Leerink Partners requested details on the commercial opportunity for tau imaging agent MK6240 and its strategic fit within the company's broader Alzheimer's franchise alongside NeuroSeq.

    Answer

    CEO Brian Markison described tau imaging's value as "unmistakable" for future patient selection and monitoring in clinical trials, with the potential for the neuro portfolio to be similar in size to Polarify. President Paul Blanchfield added that the acquired LMI team provides a strong commercial platform to launch MK6240 and lead the neuro PET diagnostic market.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Amarin Corporation PLC (AMRN) leadership

    Mazahir Alimohamed's questions to Amarin Corporation PLC (AMRN) leadership • Q2 2025

    Question

    Mazahir Alimohamed, on behalf of Roana Ruiz at Leerink Partners, questioned the realistic expectations for European market penetration over the next three to five years under the Recordati partnership and how Recordati's broader reach into primary care differentiates its approach from Amarin's previous specialty-focused strategy.

    Answer

    CEO Aaron Berg explained that it is too early to provide long-term forecasts for Europe but expressed optimism for accelerated growth. He highlighted the key strategic difference: Amarin's direct approach was limited and focused on specialists, whereas Recordati has a well-established infrastructure in both specialty cardiology and primary care. This broader reach is expected to enable a greater commercial impact and wider patient access than Amarin could have achieved alone.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Xeris Biopharma Holdings Inc (XERS) leadership

    Mazahir Alimohamed's questions to Xeris Biopharma Holdings Inc (XERS) leadership • Q1 2025

    Question

    Eason Lee, on behalf of Mazahir Alimohamed, inquired about the primary drivers of the company's operational efficiency and its sustainability, and also asked for details on the development milestones and strategy for the pipeline product XP-8121.

    Answer

    CFO Steven Pieper attributed operational efficiency to strong top-line growth, improving gross margins, and disciplined expense management, confirming the company expects to remain adjusted EBITDA positive. CEO John Shannon added that a comprehensive update on XP-8121's development pathway, regulatory strategy, and timelines will be provided at the Analyst and Investor Day on June 3.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Xeris Biopharma Holdings Inc (XERS) leadership • Q4 2024

    Question

    Mazahir Alimohamed, on for Roanna Ruiz, asked about potential plans to further expand the Recorlev sales force in 2025 and inquired about the commercial synergies between the existing product portfolio and the future launch of XP-8121.

    Answer

    CFO Steven Pieper stated that while the company will remain opportunistic, there are no firm plans for another Recorlev sales force expansion in 2025. CEO John Shannon described XP-8121 as a "perfect fit" for the company's commercial infrastructure, highlighting its ability to leverage the existing endocrinology footprint, patient support services, and proven XeriSol technology platform.

    Ask Fintool Equity Research AI